Therapeutic time window for ischemic stroke

Research output: Contribution to journalArticle

Abstract

Neuroprotection is essential for therapy in acute stage of stroke. Both neurotrophic factors (NTFs) and free radical scavenger can be such neuroprotective reagents with inhibiting death signals and potentiating survival signals under cerebral ischemia. Edaravone, a free radical scavenger, is the first clinical drug for neuroprotection in the world which has been used from 2001 in most ischemic stroke patients in Japan. Edaravone scavenges hydroxyl radicals both in hydrophilic and hydrophobic conditions, and is especially useful in thrombolytic therapy with tissue plasminogen activator (tPA). Combination therapy of Edaravone with tPA greatly increased survival of stroke animals, reduced infarct size, and inhibited molecular markers of oxidative damage in lipid, protein and DNA. Use of Edaravone greatly reduced hemorrhagic transformation accompanied by tPA treatment, and may also extend therapeutic time window with tPA therapy for more than 3 hr in human stroke patients.

Original languageEnglish
Pages (from-to)1182-1184
Number of pages3
JournalClinical Neurology
Volume51
Issue number11
DOIs
Publication statusPublished - 2011

Fingerprint

Tissue Plasminogen Activator
Stroke
Free Radical Scavengers
Therapeutics
Survival
Thrombolytic Therapy
Nerve Growth Factors
Brain Ischemia
Hydroxyl Radical
Japan
Lipids
phenylmethylpyrazolone
DNA
Pharmaceutical Preparations
Proteins
Neuroprotection

Keywords

  • Edaravone
  • Hemorrhagic transformation
  • Neuroprotection
  • tPA

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Therapeutic time window for ischemic stroke. / Abe, Koji.

In: Clinical Neurology, Vol. 51, No. 11, 2011, p. 1182-1184.

Research output: Contribution to journalArticle

Abe, Koji. / Therapeutic time window for ischemic stroke. In: Clinical Neurology. 2011 ; Vol. 51, No. 11. pp. 1182-1184.
@article{b77e0594a4ff4bada3fcd618e27cd78a,
title = "Therapeutic time window for ischemic stroke",
abstract = "Neuroprotection is essential for therapy in acute stage of stroke. Both neurotrophic factors (NTFs) and free radical scavenger can be such neuroprotective reagents with inhibiting death signals and potentiating survival signals under cerebral ischemia. Edaravone, a free radical scavenger, is the first clinical drug for neuroprotection in the world which has been used from 2001 in most ischemic stroke patients in Japan. Edaravone scavenges hydroxyl radicals both in hydrophilic and hydrophobic conditions, and is especially useful in thrombolytic therapy with tissue plasminogen activator (tPA). Combination therapy of Edaravone with tPA greatly increased survival of stroke animals, reduced infarct size, and inhibited molecular markers of oxidative damage in lipid, protein and DNA. Use of Edaravone greatly reduced hemorrhagic transformation accompanied by tPA treatment, and may also extend therapeutic time window with tPA therapy for more than 3 hr in human stroke patients.",
keywords = "Edaravone, Hemorrhagic transformation, Neuroprotection, tPA",
author = "Koji Abe",
year = "2011",
doi = "10.5692/clinicalneurol.51.1182",
language = "English",
volume = "51",
pages = "1182--1184",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "11",

}

TY - JOUR

T1 - Therapeutic time window for ischemic stroke

AU - Abe, Koji

PY - 2011

Y1 - 2011

N2 - Neuroprotection is essential for therapy in acute stage of stroke. Both neurotrophic factors (NTFs) and free radical scavenger can be such neuroprotective reagents with inhibiting death signals and potentiating survival signals under cerebral ischemia. Edaravone, a free radical scavenger, is the first clinical drug for neuroprotection in the world which has been used from 2001 in most ischemic stroke patients in Japan. Edaravone scavenges hydroxyl radicals both in hydrophilic and hydrophobic conditions, and is especially useful in thrombolytic therapy with tissue plasminogen activator (tPA). Combination therapy of Edaravone with tPA greatly increased survival of stroke animals, reduced infarct size, and inhibited molecular markers of oxidative damage in lipid, protein and DNA. Use of Edaravone greatly reduced hemorrhagic transformation accompanied by tPA treatment, and may also extend therapeutic time window with tPA therapy for more than 3 hr in human stroke patients.

AB - Neuroprotection is essential for therapy in acute stage of stroke. Both neurotrophic factors (NTFs) and free radical scavenger can be such neuroprotective reagents with inhibiting death signals and potentiating survival signals under cerebral ischemia. Edaravone, a free radical scavenger, is the first clinical drug for neuroprotection in the world which has been used from 2001 in most ischemic stroke patients in Japan. Edaravone scavenges hydroxyl radicals both in hydrophilic and hydrophobic conditions, and is especially useful in thrombolytic therapy with tissue plasminogen activator (tPA). Combination therapy of Edaravone with tPA greatly increased survival of stroke animals, reduced infarct size, and inhibited molecular markers of oxidative damage in lipid, protein and DNA. Use of Edaravone greatly reduced hemorrhagic transformation accompanied by tPA treatment, and may also extend therapeutic time window with tPA therapy for more than 3 hr in human stroke patients.

KW - Edaravone

KW - Hemorrhagic transformation

KW - Neuroprotection

KW - tPA

UR - http://www.scopus.com/inward/record.url?scp=84856504361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856504361&partnerID=8YFLogxK

U2 - 10.5692/clinicalneurol.51.1182

DO - 10.5692/clinicalneurol.51.1182

M3 - Article

C2 - 22277527

AN - SCOPUS:84856504361

VL - 51

SP - 1182

EP - 1184

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 11

ER -